Canada markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.91-0.59 (-2.51%)
At close: 04:00PM EST
22.91 0.00 (0.00%)
After hours: 04:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close23.50
Open23.17
Bid22.83 x 800
Ask22.86 x 800
Day's Range22.52 - 23.24
52 Week Range13.82 - 24.21
Volume493,696
Avg. Volume645,018
Market Cap2.054B
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

    Management will also participate in two upcoming healthcare conferencesSALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the com

  • GlobeNewswire

    Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

    Dr. Dallas Reed Myriad Genetics, Inc. today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brin

  • GlobeNewswire

    Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

    SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tu